Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Accounts Payables (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Accounts Payables for 16 consecutive years, with $556000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables changed N/A to $556000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $556000.0, a N/A change, with the full-year FY2024 number at $108000.0, down 69.58% from a year prior.
  • Accounts Payables was $556000.0 for Q3 2025 at Gyre Therapeutics, up from $108000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.4 million in Q4 2021 to a low of $5000.0 in Q2 2023.
  • A 5-year average of $1.5 million and a median of $355000.0 in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: plummeted 99.66% in 2023, then skyrocketed 1962.5% in 2024.
  • Gyre Therapeutics' Accounts Payables stood at $6.4 million in 2021, then crashed by 96.98% to $194000.0 in 2022, then surged by 82.99% to $355000.0 in 2023, then crashed by 69.58% to $108000.0 in 2024, then skyrocketed by 414.81% to $556000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Accounts Payables are $556000.0 (Q3 2025), $108000.0 (Q4 2024), and $330000.0 (Q1 2024).